How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

366 results for

Intraocular Carbonic Anhydrase Inhibitor

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Acute Orbital Compartment Syndrome (Treatment)

. Immediately employ medical therapy. Osmotic agents and carbonic anhydrase inhibitors are part of established protocols at many centers. Most experts also recommend high-dose steroid therapy as a standard of care. Less agreement exists for use of topical beta-blockers and multiple osmotic agents. Irreversible optic-nerve pathology may occur with as little as 2 hours of ischemia. Rapid employment of medical therapy and ophthalmologic consultation should proceed promptly once the diagnosis is made. Previous (...) canthal tendon (ie, inferior cantholysis), which allows complete mobility of the lower lid. Visual loss without definite signs consistent with increased IOP is not an indication for this procedure. Other primary indications for lateral canthotomy and cantholysis include an intraocular pressure (IOP) greater than 40 mm Hg and proptosis, which may be used as a criterion for unconscious patients whose visual acuity cannot be determined. Secondary criteria include afferent pupillary defect

2014 eMedicine Emergency Medicine

162. Laser-1st vs Drops-1st for Glaucoma and Ocular Hypertension

) are permitted according to a pre-specified intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary. Other Name: SLT; "Laser First" Active Comparator: Medicine-1st Conventional medical therapy [DRUG] without laser. All participants in this arm start their treatment pathway (...) or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary. Drug: Primary Medical Treatment Pathway Primary Medical Treatment Pathway (multiple medications, as required). If IOP not at target additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy ). All available medical treatments (eye-drops) are permitted according to a pre-specified intervention protocol described in detail in the publicly

2013 Clinical Trials

163. Topical Treatment of Uveitic Macular Edema

intraocular pressure-lowering medications and/or prior glaucoma surgery are acceptable) Media clarity and pupillary dilation sufficient to allow OCT testing and retinal photography Best-corrected visual acuity of 5/200 or better Patient-level Exclusion Criteria Use of oral acetazolamide or other systemic carbonic anhydrase inhibitors at baseline Known allergy or hypersensitivity to any component of the study drugs Women who are pregnant or breastfeeding (pregnancy test should be administered prior (...) defined as 20% or greater reduction in central subfield thickness by OCT or resolution of edema recurrence [ Time Frame: 4 weeks ] proportion of patients with recurrence of macular edema defined as greater than 20% increase in central subfield thickness to a value >320 microns by OCT or presence of cysts in an eye that previously had resolution of macular edema Intraocular pressure (IOP) increase [ Time Frame: 4 weeks ] number of patients with intraocular pressure increase at least 10mmHg over

2013 Clinical Trials

164. Safety Study of Aqueous Suppression After Ahmed Glaucoma Valve (AGV) Implantation

of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) ) surgery the intraocular pressure (IOP) classically goes through 2 phases. The hypotensive phase occurs immediately after surgery, lasts around 1 week. This is followed by the hypertensive period where the IOP tends to rise steadily above 21mmhg. The hypertensive response seems to occur more commonly after Ahmed GDD surgery than nonvalved implants, It was reported to occur in 40% to 80% of cases. Although the hypertensive phase can last as long as 6 months it is usually during the first 1 to 4 weeks

2013 Clinical Trials

165. Phase I/II Trial to Find Maximum Tolerated Dose (MTD) and Dose Limiting Toxicities (DLT) of TLC399 (ProDex) in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)

steroids, carbonic anhydrase inhibitors, or warfarin/heparin within 1 month prior to the Screening visit or anticipated use at any time during the study. Use of immunosuppressants, immunomodulators, antimetabolites, and/or alkylating agents within 6 months prior to the Screening visit or anticipated use at any time during the study. BCVA score < 34 letters (approximately 20/200 Snellen equivalent) in the non-study eye using the chart ETDRS method at the Screening visit. Known allergy (...) : up to 1 year ] Number of SAEs and treatment-related severe AEs Part 2: Mean change of intraocular pressure (IOP) [ Time Frame: Months 1-12 ] Evaluate the mean changes in intraocular pressure (IOP) in patients receiving TLC399 (ProDex) treatment from baseline up to 1 year Part 2: Mean change of letters read correctly (using BCVA) [ Time Frame: Months 1-12 ] Evaluate the change in BCVA from baseline up to 1 year Part 2: Change of central retinal thickness (using OCT) [ Time Frame: Months 1-12

2013 Clinical Trials

166. Economic Evaluation of Femtosecond Laser Assisted Cataract Surgery

of Central retinal vein or artery occlusion History of uveitis History of optic nerve head neuropathy except glaucoma Progressive glaucoma Nystagmus Uncontrolled diabetes mellitus General history of dementia or psychotic disorders Pregnancy, breast feeding General medications: Alpha-blockers, Carbonic anhydrase inhibitors Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact (...) procedures of one surgeon. Phacoemulsification machine used to perform cataract surgery in each center will be the same for all patients included in the center. The IOL (IntraOcular Lens) used in each center will be the same for all patients treated in the center. Experimental: Femto Corneal incision, anterior capsulorhexis and lens fragmentation by femtosecond laser Device: Femtosecond laser-assisted cataract surgery Each patients randomized in the femto arm will undergo a femtosecond laser assisted

2013 Clinical Trials

167. Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy

Patient who has active intraocular inflammation or infection Patient who has uncontrolled glaucoma IOP was more than 25 mmHg in spite of anti-glaucoma medication Visual field defect which affect best corrected visual acuity Patient who has been used systemic or topical carbonic anhydrase inhibitor within 1 month Cushing syndrome History of intravitreal steroid injection to study eye Patient who has been used or plan to use systemic drug which is toxic to crystalline lens, retina or optic nerve (...) Criteria: Clinical diagnosis of idiopathic CSC. 18 to 60 years old, woman and man. Subretinal fluid is found at OCT. Symptom duration is from 6 weeks to 4 months. Patient who agree to participate in the study. Exclusion Criteria: Patient who was treated previously for CSC Patient who has choroidal neovascularization or other macular disease Patient who has other ophthalmologic disease that may affect patient's vision. History of any intraocular surgery, except cataract extraction prior to 3 months

2013 Clinical Trials

168. Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue

Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) % ophthalmic suspension Drug: Vehicle Drug: Prostaglandin analogue Phase 4 Detailed Description: This study was divided into 2 sequential phases. The Screening/Eligibility Phase included one Screening Visit and two Eligibility Visits, during which subjects washed out of all other intraocular pressure (IOP)-lowering medications and dosed with TRAVATAN Z®, XALATAN®, or LUMIGAN®, 1 drop instilled in each eye once daily for 28 days. Subjects who met all inclusion/exclusion criteria were randomized

2013 Clinical Trials

169. Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®

of Pharmacological Action Physiological Effects of Drugs Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) Drug: Travoprost 0.004% ophthalmic solution Phase 4 Detailed Description: This study was divided into 2 sequential phases. The Screening/Eligibility Phase included one Screening Visit and two Eligibility Visits, during which subjects washed out of all other intraocular pressure (IOP)-lowering medications and dosed with TRAVATAN Z®, 1 drop instilled in each eye once daily for 28 days. Subjects who met all inclusion/exclusion criteria were randomized at the second Eligibility Visit. The Treatment

2013 Clinical Trials

170. Impact of a Tolerability Switch to Dorzolamide/Timolol Preservative-free Fixed Combination on Ocular Surface Symptoms

table for MeSH terms Glaucoma Glaucoma, Open-Angle Ocular Hypertension Eye Diseases Timolol Dorzolamide Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) topical intraocular pressure lowering therapy and that were scheduled to switch current therapy to preservative-free DTFC. Outcome Measures Go to Primary Outcome Measures : Change in Glaucoma Symptom Scale questionnaire [ Time Frame: 8 weeks ] The main study objective was to assess a change in the patient-reported Glaucoma Symptom Scale questionnaire, filled in at baseline (Week 0) and at the end of the 8 week of therapy with preservative-free DTFC. Secondary Outcome Measures : Change in Functional

2013 Clinical Trials

171. Immediate Anterior Chamber Paracentesis With A 30-Gauge Needle for Acute Primary Angle

by Naris Kitnarong, Siriraj Hospital: paracentesis primary acute angle closure iridotomy filtration glaucoma Additional relevant MeSH terms: Layout table for MeSH terms Glaucoma Glaucoma, Angle-Closure Ocular Hypertension Eye Diseases Acetazolamide Anticonvulsants Carbonic Anhydrase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Diuretics Natriuretic Agents Physiological Effects of Drugs (...) will be adjusted according to the level of IOP. The maximal dose is 4 tablets per day. It will be discontinued if the IOP is less than 21 mmHg. All affected eyes will receive laser peripheral iridotomy with 24 hours after presentation. This a standard treatment for Acute angle-closure glaucoma Procedure: Paracentesis At presentation, patients received immediate anterior chamber paracentesis with a 30-gauge needle. The intraocular pressure (IOP) was recorded at immediately, 15 and 30 minutes, and then 1, 24

2013 Clinical Trials

172. Transconjunctival Needling Revision Versus Medical Treatment

with sweeping movement up and down, back and forth. Active Comparator: Medical treatment Eyes with primary glaucoma surgery failure with encapsulated blebs were treated with medical treatment (hypotensive eye drops) Drug: Medical treatment Hypotensive eye drops are initialized one by one regarding intraocular pressure control. Nonspecific beta blocker and/or prostaglandin, followed by carbonic anhydrase inhibitors and/or selective alpha agonist. Other Names: Timoptol 0,5% Xalatan Trusopt Alphagan Outcome (...) of Sao Paulo General Hospital Study Details Study Description Go to Brief Summary: When the glaucoma filtering surgery failures (intraocular pressure rises again), the options is start to use the hypotensive eye drops again (medical treatment). However, in some cases (encapsulated blebs), there is a simple surgical revision that can revival the primary failure surgery. It calls transconjunctival needling revision. In this study, the investigators compare the efficacy of this revision versus medical

2013 Clinical Trials

173. Orbscan topography in primary open-angle glaucoma. (Abstract)

included any corneal or ocular inflammatory disease, previous ocular surgery, or treatment with carbonic anhydrase inhibitors. The same masked observer performed Goldmann applanation tonometry, ultrasound pachymetry, and Orbscan II topography in all cases. Central corneal thickness, intraocular pressure, and anterior and posterior topographic elevation maps were analyzed and compared between both groups.Patients with POAG had greater forward shifting of the posterior corneal surface than

2013 Optometry and vision science : official publication of the American Academy of Optometry Controlled trial quality: uncertain

174. Association of ocular hypotensive medication types with dynamic contour tonometry and Goldmann applanation tonometry measurements in a glaucoma and ocular hypertensive population. (Abstract)

, respectively. The number of IOP-lowering agents did not have any statistically significant influence on ΔIOP (p=0.177), DCT (P=0.28) and GAT (P=0.13) measurements. A statistically higher ΔIOP was revealed in monotherapy patients receiving Carbonic Anhydrase Inhibitors (CAIs) (ΔIOP=5.75 mmHg) in comparison to patients receiving Prostaglandin Analogs (ΔIOP=4.09 mm Hg) or beta Blockers (ΔIOP=3.78 mmHg) as single topical therapy (F=4.373, P=0.005). Eyes treated with CAIs as a part of the ocular hypotensive (...) Association of ocular hypotensive medication types with dynamic contour tonometry and Goldmann applanation tonometry measurements in a glaucoma and ocular hypertensive population. The aim of this study was to evaluate the association between different intraocular pressure (IOP)-lowering medications and IOP measurements by dynamic contour tonometry (DCT) and Goldmann applanation tonometry (GAT) in a glaucoma and ocular hypertensive population.In a prospective, observational case series study

2013 Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics

175. Acetazolamide

occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337) Definition (CSP) carbonic anhydrase inhibitor that is sometimes effective against (...) From Related Chapters II. Mechanism Carbonic Anhydrase Inhibitor III. Indications treatment and prevention IV. Contraindications V. Dosing Prevention: 125 mg PO bid Start 24 hours before ascent Continue for 72 hours or until acclimitization to highest sleeping altitude at altitude: 125 mg PO qhs Treatment: 250 mg orally twice daily (up to 400 mg twice daily has been sed) Dose range: 125-250 mg PO qd-tid VI. Adverse Effects Peripheral s (common) Images: Related links to external sites (from Bing

2015 FP Notebook

176. Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial. Full Text available with Trip Pro

study. We randomly allocated 39 patients who had been treated with three antiglaucoma eye drops (prostaglandin F(2α) analogues plus beta-blockers and carbonic anhydrase inhibitors) into two groups. Group A (n = 20) were treated with latanoprost-timolol and brinzolamide 1% therapy and Group B (n = 16) were treated with dorzolamide 1%/timolol and latanoprost. Thirty-six patients completed all 12 weeks of this study. The major clinical parameters measured were intraocular pressure (IOP), conjunctive

2012 Clinical ophthalmology (Auckland, N.Z.) Controlled trial quality: uncertain

177. Secondary neuroprotective effects of hypotensive drugs and potential mechanisms of action Full Text available with Trip Pro

, β-antagonists, prostaglandin analogs and carbonic anhydrase inhibitors. Some of these topical medications exhibit secondary neuroprotective effects independent of their effect on IOP. This review covers the possible mechanisms of neuroprotection stimulated by drugs currently marketed for the lowering of IOP, based on known literature. While the neuroprotective properties of many glaucoma pharmaceuticals are promising from an experimental standpoint, key challenges for the development of new (...) Secondary neuroprotective effects of hypotensive drugs and potential mechanisms of action Primary open-angle glaucoma, a long-term degenerative ocular neuropathy, remains a significant cause of vision impairment worldwide. While many risk factors have been correlated with increased risk for primary open-angle glaucoma, intraocular pressure (IOP) remains the only modifiable risk factor and primary therapeutic target. Pharmacologic therapies are administered topically; these include α(2)-agonists

2012 Expert review of ophthalmology

178. The Laser in Pseudoexfoliation (LIP) Study

IOP, a second line agent will be added (β-Blocker unless contraindicated). If target IOP is still not reached, a third agent will be considered (topical carbonic anhydrase inhibitor). Treatment may be switched, instead, at the discretion of the clinician if the reduction of IOP with an agent is deemed to be no different than the pre-treatment IOP. Surgical therapy will be considered if target IOP is not met, or there is high IOP (>35 mmHg) or advanced damage at presentation. Other Names: B-Blocker (...) Carbonic anydrase inhibitor Outcome Measures Go to Primary Outcome Measures : Number of drops (and surgical interventions) needed to reach target IOP. [ Time Frame: Change in IOP at 6 months, 12 months and 2 years (from baseline). ] Percentage success [ Time Frame: At 6 months, 12 months and 2 years ] Proportion of patients in whom SLT (or mono medical therapy) alone achieved target IOP. Secondary Outcome Measures : Correlation of angle pigment grade with IOP reduction from SLT [ Time Frame: 6 months

2012 Clinical Trials

179. Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America

Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Enzyme Inhibitors Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Carbonic Anhydrase Inhibitors (...) of Medicine related topics: related topics: available for: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: AZARGA® Brinzolamide/timolol maleate fixed combination, 1 drop self-administered in study eye(s) twice a day for 8 weeks Drug: Brinzolamide/timolol maleate fixed combination Other Name: AZARGA® Outcome Measures Go to Primary Outcome Measures : Mean Change in Intraocular Pressure (IOP) From Baseline (Prior Therapy) at Week 8 [ Time Frame: Baseline, Week 8 ] IOP (fluid

2012 Clinical Trials

180. Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves

gtts in study eye BID OR timolol 0.5% 1 gtts in study eye BID). Next, a topical carbonic anhydrase inhibitor eye drop. (brinzolamide 1% 1 gtts in study eye TID OR dorzolamide 2% 1 gtts in study eye TID) Next, a topical alpha agonist eye drop. (brimonidine 0.1% 1 gtts in study eye TID OR brimonidine 0.15% 1 gtts in study eye TID). Next, a topical prostaglandin analogue eye drop. (latanoprost 0.005% 1 gtts in study eye qhs OR travoprost 0.004% 1 gtts in study eye qhs OR bimatoprost 0.01% 1 gtts (...) in study eye qhs OR bimatoprost 0.03% 1 gtts in study eye qhs) Finally, stop the topical carbonic anhydrase inhibitor eye drop and start oral acetazolamide. (acetazolamide 250mg PO OD) Other Names: Timoptic Trusopt Azopt Alphagan-P Xalatan Travatan Z Lumigan Diamox No Intervention: Control Group Patients randomized to the control group will receive standard of care treatment. They will not be aqueous suppressed within the first three postoperative months unless the bleb hyperencapsulates

2012 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>